# CRL tracker: FDA complete response letters

Canonical: https://sec-api.dev/crl-tracker

> 108 complete response letters were disclosed in the last 24 months. The most recent: ivonescimab (SMMT) on November 15, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the latest FDA complete response letter?

108 complete response letters were disclosed in the last 24 months. The most recent: ivonescimab (SMMT) on November 15, 2026. [Calendar and source filings](https://sec-api.dev/crl-tracker)

Source: SEC Form 8-K, accession 0001599298-26-000092, https://www.sec.gov/Archives/edgar/data/1599298/000159929826000092/smmt-20261115.htm (retrieved 2026-11-16). Last confirmed 2026-11-16. Cite: https://sec-api.dev/crl-tracker#answer

## Complete response letters

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 15, 2026 | [Ivonescimab complete response letter (CRL)](https://sec-api.dev/pdufa/ivonescimab) | SMMT | with locally advanced or metastatic non-small cell lung cancer | completed, complete response letter | "On November 15, 2026, Summit Therapeutics Inc. issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has issued a Complete Response Letter ("CRL") regarding the Biologics License Application ("BLA") for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, who have received prior epidermal growth factor receptor tyrosine kinase inhibitor therapy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000092/smmt-20261115.htm)) |
| November 10, 2026 | [Release (release) complete response letter (CRL)](https://sec-api.dev/pdufa/release) | CING |  | completed, complete response letter | "November 10, 2026, Cingulate Inc. (Company) issued a press release announcing that its Chairman and CEO, Shane J. Schaffer, in an interview on Innovators with Jane King discusses the Company's ongoing efforts to address the U.S. Food and Drug Administration's (FDA) Complete Response Letter (CRL) regarding the CTx-1301 new drug application (NDA), progress made to date, and the anticipated timeline for NDA resubmission." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226050870/form8-k.htm)) |
| September 29, 2026 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed, complete response letter | "Based on the Type D meeting, on September 29, 2026, Aldeyra issued a press release (the Press Release) announcing the intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs (OND), appealing the March 16, 2026 Complete Response Letter that denied approval of a New Drug Application for reproxalap for the treatment of dry eye disease, and the extension of Aldeyra's projected operational cash runway into 2029." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526405954/aldx-20260929.htm)) |
| September 11, 2026 | [ACADIA PHARMACEUTICALS INC complete response letter (CRL)](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed, complete response letter | "And, on April 5, 2021, Acadia announced that the FDA had issued a Complete Response Letter ("CRL"), stating that it could not approve the sNDA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526389400/d143428dex991.htm)) |
| August 7, 2026 | [ITM-11 complete response letter (CRL)](https://sec-api.dev/pdufa/itm-11) | TLX |  | completed, complete response letter | "ITM-11 U.S. regulatory status CRL received on August 7, 2026 is limited to CMC and third-party facility items and no clinical or nonclinical deficiencies were identified CRL scope FDA cited Chemistry, Manufacturing and Controls (CMC) and third-party commercial facility inspection- related items Clinical package No clinical safety or efficacy issues were identified, and no additional clinical or nonclinical data were requested Remediation ITM is reviewing the feedback and coordinating with relevant external parties to address the cited items Resubmission ITM intends to resubmit the NDA to complete FDA review; timing remains subject to remediation and agency interaction." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026068291/a20261030tlxnoticeofgene.htm)) |
| Aug 2026 | [Clemidsogene lanparvovec complete response letter (CRL)](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | completed, complete response letter | "In August 2026, an amended complaint was filed focusing on interactions with FDA and Company statements prior to the Company's receipt of a Complete Response Letter for RGX-121 in February 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590877/000119312526448581/rgnx-20260930.htm)) |
| July 28, 2026 | [Nimodipine complete response letter (CRL)](https://sec-api.dev/pdufa/nimodipine) | GRCE |  | completed, complete response letter | "Princeton, NJ, July 28, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced receipt of the U.S. Food and Drug Administration (FDA) meeting minutes from a Type A Meeting held with the FDA to discuss the Complete Response Letter (CRL) issued on April 23, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126029837/ef20078866_ex99-1.htm)) |
| Jul 2026 | [Grace Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed, complete response letter | "Following a Type A meeting with the FDA regarding the CRL, we received the FDA's official meeting minutes in July 2026, constituting the official record of the meeting." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1444192/000114036126043299/ef20080550_10q.htm)) |
| June 30, 2026 | [Unicycive Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed, complete response letter | "On June 30, 2026, we announced that we received a CRL from the FDA regarding the resubmitted NDA for OLC." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm)) |
| June 30, 2026 | [Inluriyo™ (imlunestrant) complete response letter (CRL)](https://sec-api.dev/pdufa/imlunestrant) | LONA |  | completed, complete response letter | "The Series A Common Warrants have an exercise price of $6.35 per share and are exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Company publicly announces the enrollment of the 500th subject or the last subject, whichever is earlier, in the ELAINE-3 trial; and (c) the date on which the FDA approves or issues a complete response letter to Eli Lilly & Co.'s marketing application, including a supplement to a new drug application, for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 ( the "Series A Common Warrant Initial Exercise Date")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1620463/000119312526352243/lona-20260630.htm)) |
| June 29, 2026 | [Nda218607 complete response letter (CRL)](https://sec-api.dev/pdufa/nda218607) | UNCY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218607_20260629.pdf%22)) |
| June 20, 2026 | [Nda218995 complete response letter (CRL)](https://sec-api.dev/pdufa/nda218995) | QUIT |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218995_20260620_Redacted.pdf%22)) |
| June 2, 2026 | [Cingulate Inc. complete response letter (CRL)](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed, complete response letter | "June 2, 2026, the Company announced that the FDA has issued a CRL for its New Drug Application for CTx-1301." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/form8-k.htm)) |
| June 2, 2026 | [PTR (ptr) complete response letter (CRL)](https://sec-api.dev/pdufa/ptr) | CING | Attention Deficit/Hyperactivity Disorder | completed, complete response letter | "CITY, Kan., June 2, 2026 — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter for its New Drug Application ("NDA") for CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/ex99-1.htm)) |
| June 1, 2026 | [Indegene complete response letter (CRL)](https://sec-api.dev/pdufa/indegene) | CING |  | completed, complete response letter | "June 1, 2026, the FDA issued a Complete Response Letter (CRL) for the CTx-1301 (dexmethylphenidate HCl) NDA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm)) |
| May 29, 2026 | [Release (release) complete response letter (CRL)](https://sec-api.dev/pdufa/release) | CING |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA220283_20260529_Redacted.pdf%22)) |
| May 7, 2026 | [Cingulate Inc. complete response letter (CRL)](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed, complete response letter | "From time to time, beginning on May 7, 2026, Avondale may redeem a portion of the 2025 Note, not to exceed an amount of $660,000 per month; and provided that we have not previously received a "complete response letter" from the FDA with respect to CTx-1301, we may defer up to two redemptions for up to thirty (30) days each." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1862150/000149315226037606/form10-q.htm)) |
| April 29, 2026 | [AbbVie Inc. complete response letter (CRL)](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed, complete response letter | "•AbbVie announced it received a Complete Response Letter (CRL) from the FDA regarding the Biologics License Application (BLA) for trenibotulinumtoxinE (trenibotE), a first-in-class botulinum neurotoxin serotype E with a rapid onset of effect and short duration." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000013/abbv-20260331xexhibit991.htm)) |
| April 23, 2026 | [Nda220304 complete response letter (CRL)](https://sec-api.dev/pdufa/nda220304) | GRCE |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA220304_20260423_Redacted.pdf%22)) |
| April 23, 2026 | [GTX-104 complete response letter (CRL)](https://sec-api.dev/pdufa/gtx-104) | GRCE | with aSAH | completed, complete response letter | "On April 23, 2026, the FDA issued a CRL for the Company's NDA for GTx-104 for the treatment of patients with aSAH." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/ef20076145_ex99-1.htm)) |
| April 23, 2026 | [Nimodipine complete response letter (CRL)](https://sec-api.dev/pdufa/nimodipine) | GRCE | with aSAH | completed, complete response letter | "Princeton, NJ, April 23, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's New Drug Application (NDA) for GTx-104 for the treatment of patients with aSAH." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126016324/ef20070593_ex99-1.htm)) |
| April 23, 2026 | [Grace Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed, complete response letter | "April 23, 2026, the Company received a CRL from the FDA in response to their" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1444192/000114036126025662/ef20070498_10k.htm)) |
| April 22, 2026 | [AGN-151586 complete response letter (CRL)](https://sec-api.dev/pdufa/agn-151586) | ABBV |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761459_20260422.pdf%22)) |
| April 10, 2026 | [Vusolimogene oderparepvec complete response letter (CRL)](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 04/10/2026 for BL 125827 to Replimune, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125827_20260410.pdf%22)) |
| April 10, 2026 | [Opdivo® (nivolumab) complete response letter (CRL)](https://sec-api.dev/pdufa/nivolumab) | REPL | advanced melanoma | completed, complete response letter | "On April 10, 2026 the Company received a CRL from the FDA for the BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm)) |
| April 10, 2026 | [Bla761401 complete response letter (CRL)](https://sec-api.dev/pdufa/bla761401) | TLX |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761401_20260410.pdf%22)) |
| March 16, 2026 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA216442_20260316.pdf%22)) |
| March 10, 2026 | [Deramiocel complete response letter (CRL)](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed, complete response letter | "On March 10, 2026, Capricor Therapeutics, Inc. (the "Company" or "Caprcior") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has lifted the previously issued Complete Response Letter ("CRL") and resumed review of its Biologics License Application ("BLA") seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of Duchenne muscular dystrophy ("DMD") cardiomyopathy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm)) |
| February 27, 2026 | [ZYNYZ (retifanlimab) complete response letter (CRL)](https://sec-api.dev/pdufa/retifanlimab) | INCY |  | completed, complete response letter | "On February 27, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for the supplemental Biologics License Application ("sBLA") for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer ("NSCLC") in combination with platinum-based chemotherapy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/879169/000087916926000013/incy-20260227.htm)) |
| February 26, 2026 | [We complete response letter (CRL)](https://sec-api.dev/pdufa/we) | AMPH |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761403_20260226.pdf%22)) |
| February 13, 2026 | [Nda220707 complete response letter (CRL)](https://sec-api.dev/pdufa/nda220707) | IRON |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA220707_20260213.pdf%22)) |
| February 13, 2026 | [Bitopertin complete response letter (CRL)](https://sec-api.dev/pdufa/bitopertin) | IRON | erythropoietic protoporphyria | completed, complete response letter | "On February 13, 2026, Disc Medicine, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for the New Drug Application ("NDA") for bitopertin as a treatment for patients with erythropoietic protoporphyria ("EPP")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/iron-20260213.htm)) |
| February 7, 2026 | [Clemidsogene complete response letter (CRL)](https://sec-api.dev/pdufa/clemidsogene) | RGNX |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 02/07/2026 for BL 125840 to REGENXBIO, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125840_20260207.pdf%22)) |
| February 7, 2026 | [Clemidsogene lanparvovec complete response letter (CRL)](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | completed, complete response letter | "On February 7, 2026, the Company received a CRL from the FDA regarding the Company's BLA for RGX-121, the Company's investigational gene therapy for Mucopolysaccharidosis type II." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590877/000119312526043342/rgnx-20260207.htm)) |
| February 2, 2026 | [Anaphylm™ (dibutepinephrine) complete response letter (CRL)](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type I allergic reactions | completed, complete response letter | "On February 2, 2026, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026, for the New Drug Application (NDA) seeking approval of Anaphylm™ (dibutepinephrine) Sublingual Film for the treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more (approximately 66 pounds)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000005/aqst-20260130.htm)) |
| February 1, 2026 | [Joenja® (leniolisib) complete response letter (CRL)](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, complete response letter | "Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000004/pharminggroupreceivescompl.htm)) |
| January 30, 2026 | [Nda219870 complete response letter (CRL)](https://sec-api.dev/pdufa/nda219870) | AQST |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219870_20260130.pdf%22)) |
| January 30, 2026 | [Pharming Group N.V. complete response letter (CRL)](https://sec-api.dev/companies/phar/catalysts) | PHAR |  | completed, complete response letter | "Following the Complete Response Letter (CRL) received on January 30, 2026, and a subsequent Type A meeting with the FDA on March 26, 2026, the resubmission seeks approval of 40 mg and 50 mg twice-daily dosing for pediatric patients weighing 27 kg or more, who represent a meaningful proportion of the identified pediatric patient population." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000031/pharmingannouncesusfdaacce.htm)) |
| January 30, 2026 | [AQST-108 complete response letter (CRL)](https://sec-api.dev/pdufa/aqst-108) | AQST |  | completed, complete response letter | "Until profitability is achieved, if at all, additional capital and/or other financing or funding will be required, which could be material, to develop and commercialize our product pipeline, including AQST-108, to fund additional development and commercial activities, and that are required by the FDA for Anaphylm under the CRL issued to the Company on January 30, 2026, and to meet our other cash requirements, including debt service." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm)) |
| January 28, 2026 | [Nda219398 complete response letter (CRL)](https://sec-api.dev/pdufa/nda219398) | CORT |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219398_20260128.pdf%22)) |
| January 12, 2026 | [Tab-cel (tabelecleucel) complete response letter (CRL)](https://sec-api.dev/pdufa/tabelecleucel) | ATRA | relapsed or refractory EBV+ PTLD | completed, complete response letter | "Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257dex991.htm)) |
| Jan 2026 | [Indegene complete response letter (CRL)](https://sec-api.dev/pdufa/indegene) | CING |  | completed, complete response letter | "FDA issued a Complete Response Letter for the CTx-1301 NDA; the Company and its CDMO have since substantially completed the manufacturing work required to address the CMC requests, and the Company expects to resubmit the NDA between December 2026 and January 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm)) |
| Jan 2026 | [ATA3219 complete response letter (CRL)](https://sec-api.dev/pdufa/ata3219) | ATRA |  | completed, complete response letter | "In January 2026, we received the Second Complete Response Letter claiming that the ALLELE trial, previously confirmed by the FDA as adequate to support the BLA filing, is no longer considered to be an adequate and well-controlled study due to deficiencies in study design," ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm)) |
| December 31, 2025 | [Corcept complete response letter (CRL)](https://sec-api.dev/pdufa/corcept) | CORT | hypertension secondary to hypercortisolism | completed, complete response letter | "On December 31, 2025, Corcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1088856/000119312525338184/d50993d8k.htm)) |
| December 31, 2025 | [Amneal Pharmaceuticals, Inc. complete response letter (CRL)](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed, complete response letter | "(4)For the year ended December 31, 2025, asset impairment charges were primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/amrx-q22026ex991.htm)) |
| December 30, 2025 | [Outlook Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed, complete response letter | ""Company") issued a press release announcing that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL)" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465926040387/tm2611268d1_8k.htm)) |
| December 30, 2025 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761320_20251230.pdf%22)) |
| December 30, 2025 | [Avt03 complete response letter (CRL)](https://sec-api.dev/pdufa/avt03) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761471_20251230.pdf%22)) |
| December 23, 2025 | [Tolebrutinib complete response letter (CRL)](https://sec-api.dev/pdufa/tolebrutinib) | SNY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219624_20251223.pdf%22)) |
| December 16, 2025 | [Exdensur (depemokimab-ulaa) complete response letter (CRL)](https://sec-api.dev/pdufa/depemokimab-ulaa) | GSK |  | completed, complete response letter | "We have completed the review of BLA 761458/Original 2 and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761458_20251216.pdf%22)) |
| November 26, 2025 | [Avto5 complete response letter (CRL)](https://sec-api.dev/pdufa/avto5) | ALVO |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761461_20251126.pdf%22)) |
| November 24, 2025 | [Avt06 complete response letter (CRL)](https://sec-api.dev/pdufa/avt06) | ALVO |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761435_20251124.pdf%22)) |
| November 4, 2025 | [Nda210862 complete response letter (CRL)](https://sec-api.dev/pdufa/nda210862) | BHVN |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 11/04/2025 for NDA 210862 to Biohaven Therapeutics, Ltd.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA210862_20251104.pdf%22)) |
| November 2, 2025 | [Aria® (golimumab) complete response letter (CRL)](https://sec-api.dev/pdufa/golimumab) | ALVO |  | completed, complete response letter | "REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325006876/exh_991.htm)) |
| Nov 2025 | [VYGLXIA (troriluzole) complete response letter (CRL)](https://sec-api.dev/pdufa/troriluzole) | BHVN |  | completed, complete response letter | "In November 2025, we received a Complete Response Letter ("CRL") for the NDA seeking approval of troriluzole for SCA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm)) |
| Nov 2025 | [Bitopertin complete response letter (CRL)](https://sec-api.dev/pdufa/bitopertin) | IRON |  | completed, complete response letter | "The U.S. Food and Drug Administration, or the FDA, accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm)) |
| October 31, 2025 | [Avto5 complete response letter (CRL)](https://sec-api.dev/pdufa/avto5) | ALVO |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761462_20251031.pdf%22)) |
| October 28, 2025 | [Oxylanthanum complete response letter (CRL)](https://sec-api.dev/pdufa/oxylanthanum) | UNCY | kidney disease | completed, complete response letter | "On October 28, 2025, we announced an update from our meeting with the U.S. Food and Drug Administration (FDA) and timing of the resubmission of our New Drug Application (NDA) for Oxylanthanum carbonate (OLC) following receipt of a CRL on June 30, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm)) |
| October 23, 2025 | [Blenrep (belantamab mafodotin-blmf) complete response letter (CRL)](https://sec-api.dev/pdufa/belantamab-mafodotin-blmf) | GSK |  | completed, complete response letter | "We have completed the review of BLA 761440/Original 2, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761440_20251023.pdf%22)) |
| October 16, 2025 | [Zimrixby (rituximab-cdxx) complete response letter (CRL)](https://sec-api.dev/pdufa/rituximab-cdxx) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761376_20251016.pdf%22)) |
| October 10, 2025 | [Saphnelo (anifrolumab-fnia) complete response letter (CRL)](https://sec-api.dev/pdufa/anifrolumab-fnia) | AZN |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761451_20251010.pdf%22)) |
| October 1, 2025 | [ZYCUBO (CUTX-101) complete response letter (CRL)](https://sec-api.dev/pdufa/cutx-101) | FBIO | Menkes disease in pediatric patients | completed, complete response letter | "On October 1, 2025, Fortress Biotech, Inc. issued a press release announcing that the U.S. Food and Drug Administration issued a complete response letter for CUTX-101 (copper histidinate)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1429260/000110465925095366/fbio-20251001x8k.htm)) |
| September 30, 2025 | [Amneal Pharmaceuticals, Inc. complete response letter (CRL)](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed, complete response letter | "For the three months ended September 30, 2025 and the year ended December 31, 2025, asset impairment charges were primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000119312526168231/d126526dex991.htm)) |
| September 23, 2025 | [ISEMBYLD (apitegromab) complete response letter (CRL)](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | completed, complete response letter | "On September 23, 2025, the Company announced that the FDA has issued a CRL regarding the BLA for apitegromab for the treatment of SMA." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1727196/000110465925092317/tm2526733d1_8k.htm)) |
| September 22, 2025 | [SPINRAZA (nusinersen) complete response letter (CRL)](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA209531_20250922.pdf%22)) |
| September 22, 2025 | [Isembyld (apitegromab-mstn) complete response letter (CRL)](https://sec-api.dev/pdufa/apitegromab-mstn) | SRRK |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve tl action be! his application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761463_20250922.pdf%22)) |
| September 18, 2025 | [Replimune Group, Inc. complete response letter (CRL)](https://sec-api.dev/companies/repl/catalysts) | REPL |  | completed, complete response letter | "On September 18, 2025 we announced that, following the type A meeting with the FDA to discuss the CRL, which was conducted on September 16, 2025, we were evaluating feedback received during the meeting to determine our next steps and that, at that time, a path forward under the accelerated approval pathway had not been determined." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm)) |
| late 2025 | [Oxylanthanum PDUFA date](https://sec-api.dev/pdufa/oxylanthanum) | UNCY |  | completed, complete response letter | "- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/ea024208101ex99-1_unicycive.htm)) |
| Sep 2025 | [TRUXIMA® (rituximab) complete response letter (CRL)](https://sec-api.dev/pdufa/rituximab) | RDY |  | completed, complete response letter | "Received a CRL for rituximab biosimilar BLA, in reference to the ongoing resolution of observations arising from the Pre Approval Inspection (PAI) of our Biologics facility at Bachupally, Hyderabad, Telangana, India conducted in September 2025, as well as certain aspects pertaining to the BLA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000034/rdy0840_ex99-1.htm)) |
| Sep 2025 | [Scholar Rock Holding Corp complete response letter (CRL)](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed, complete response letter | "In September 2025, we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm)) |
| August 31, 2025 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed, complete response letter | "Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm)) |
| August 27, 2025 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed, complete response letter | "Inc (the "Company") issued a press release announcing that it has completed the requested Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925094558/tm2527376d1_8k.htm)) |
| August 19, 2025 | [Vatiquinone complete response letter (CRL)](https://sec-api.dev/pdufa/vatiquinone) | PTCT | children and adults living with Friedreich's ataxia | completed, complete response letter | "WARREN, N.J., August 19, 2025 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000155837025011658/tmb-20250819xex99d1.htm)) |
| August 18, 2025 | [Nda220049 complete response letter (CRL)](https://sec-api.dev/pdufa/nda220049) | PTCT |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA220049_20250818.pdf%22)) |
| August 18, 2025 | [FAYUVI (rebisufligene etisparvovec) PDUFA date](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE |  | completed, complete response letter | "UX111, an investigational treatment for Sanfilippo syndrome, biologics license application (BLA) on track for PDUFA action date of August 18, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-ex99_1.htm)) |
| August 4, 2025 | [TLX250 complete response letter (CRL)](https://sec-api.dev/pdufa/tlx250) | TLX |  | completed, complete response letter | "In August 2025, the FDA issued a Complete Response Letter ("CRL"), citing deficiencies relating to the Chemistry, Manufacturing, and Controls ("CMC") package." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| Aug 2025 | [Deramiocel complete response letter (CRL)](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | completed, complete response letter | "Recent Type A meeting with FDA: In August 2025, Capricor held a Type A meeting with FDA following receipt of a Complete Response Letter (CRL) for its Biologics License Application (BLA) for Deramiocel." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/capr-20251110xex99d1.htm)) |
| Aug 2025 | [Eylea® (eylea) PDUFA date](https://sec-api.dev/pdufa/eylea) | REGN | macular edema | completed, complete response letter | "•The Company now expects regulatory approvals to be delayed for its currently pending FDA applications for EYLEA HD (pre-filled syringe, every-four-week dosing, and for the treatment of macular edema following retinal vein occlusion), which have PDUFA dates in August 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| Aug 2025 | [Outlook Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed, complete response letter | "Based on our productive meeting with the FDA in September, we believe this resubmission will resolve the outstanding issue highlighted in the Complete Response Letter (CRL) we received in August 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925105633/tm2530088d1_ex99-1.htm)) |
| Aug 2025 | [Girentuximab complete response letter (CRL)](https://sec-api.dev/pdufa/girentuximab) | TLX |  | completed, complete response letter | "Zircaix® (TLX250-Px, 89Zr-DFO-girentuximab): Participated in two Type A meetings with the FDA to address deficiencies identified in the CRL received in August 2025 for Telix's ccRCC PET imaging candidate16." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| July 30, 2025 | [Ordspono™ (odronextamab) complete response letter (CRL)](https://sec-api.dev/pdufa/odronextamab) | REGN |  | completed, complete response letter | "•On July 30, 2025, the FDA issued a Complete Response Letter (CRL) for the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy, which was also impacted by the Catalent Indiana LLC site inspection (as described above)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| July 30, 2025 | [Degevma (denosumab-adet) complete response letter (CRL)](https://sec-api.dev/pdufa/denosumab-adet) | TEVA |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761385_20250730.pdf%22)) |
| July 22, 2025 | [Replimune Group, Inc. complete response letter (CRL)](https://sec-api.dev/companies/repl/catalysts) | REPL | advanced melanoma | completed, complete response letter | "The complaint, captioned Jboor v. Replimune Group, Inc. et al., Case No. 1:25-cv-12085-JEK, was filed shortly after the Company announced it received a complete response letter from the FDA for its RP1 BLA for the treatment of advanced melanoma on July 22, 2025 and the subsequent decline in the trading price of the Company's common stock." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1737953/000162828026067722/repl-20260930.htm)) |
| July 22, 2025 | [Lanreotide complete response letter (CRL)](https://sec-api.dev/pdufa/lanreotide) | AMRX |  | completed, complete response letter | "For 2025, asset impairment charges primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000035/amrx-q32026ex991.htm)) |
| July 21, 2025 | [Vusolimogene oderparepvec complete response letter (CRL)](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL | advanced melanoma | completed, complete response letter | "COMPLETE RESPONSE letter dated 07/21/2025 for BL 125827 to Replimune, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125827_20250721.pdf%22)) |
| July 21, 2025 | [Opdivo® (nivolumab) complete response letter (CRL)](https://sec-api.dev/pdufa/nivolumab) | REPL | advanced melanoma in July 2025 | completed, complete response letter | "The resubmission is considered by the FDA to be a complete response to the complete response letter received on July 21, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/tm2530417d1_ex99-1.htm)) |
| July 11, 2025 | [CARDAMYST (etripamil) complete response letter (CRL)](https://sec-api.dev/pdufa/etripamil) | MIST | with paroxysmal supraventricular tachycardia | completed, complete response letter | "On July 11, 2025, we announced that the FDA accepted for review our response to issues raised in the CRL for CARDAMYST™ (etripamil) nasal spray, an investigational, novel therapy for the treatment of patients with paroxysmal supraventricular tachycardia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm)) |
| July 9, 2025 | [Deramiocel complete response letter (CRL)](https://sec-api.dev/pdufa/deramiocel) | CAPR | cardiomyopathy associated with Duchenne muscular dystrophy | completed, complete response letter | "COMPLETE RESPONSE letter dated 07/09/2025 for BL 125842 to Capricor, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125842_20250709.pdf%22)) |
| July 7, 2025 | [FAYUVI (rebisufligene etisparvovec) complete response letter (CRL)](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 07/07/2025 for BL 125845 to Ultragenyx Pharmaceutical Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125845_20250707.pdf%22)) |
| Jul 2025 | [CAPRICOR THERAPEUTICS, INC. complete response letter (CRL)](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed, complete response letter | "In July 2025, the Company received a Complete Response Letter ("CRL") from the FDA stating that the current BLA did not meet the statutory requirement for substantial evidence of effectiveness and that additional clinical data would be required." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1133869/000110465925109298/capr-20250930x10q.htm)) |
| June 30, 2025 | [Oxylanthanum complete response letter (CRL)](https://sec-api.dev/pdufa/oxylanthanum) | UNCY | Hyperphosphatemia in Patients with Chronic Kidney Disease | completed, complete response letter | "Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025059303/ea024746901ex99-1_unicycive.htm)) |
| June 27, 2025 | [Nda218607 complete response letter (CRL)](https://sec-api.dev/pdufa/nda218607) | UNCY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218607_20250627.pdf%22)) |
| Jun 2025 | [UNI-494 complete response letter (CRL)](https://sec-api.dev/pdufa/uni-494) | UNCY |  | completed, complete response letter | "The 2026 CRL cited the same third-party manufacturing deficiencies identified in a previous CRL issued in June 2025 to the initial NDA submission, as a result of the FDA not having conducted the reinspection of the original third-party manufacturing vendor." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026104314/ea030696701ex99-1.htm)) |
| April 27, 2025 | [TLX101 complete response letter (CRL)](https://sec-api.dev/pdufa/tlx101) | TLX |  | completed, complete response letter | "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for its New Drug Application (NDA) for TLX101-CDx (Floretyrosine F18 or 18F-FET, Pixclara®1), an investigational agent for the imaging of glioma, a rare and life-threatening brain cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000049/pixpr.htm)) |
| April 25, 2025 | [Pixclara (floretyrosine f-18) complete response letter (CRL)](https://sec-api.dev/pdufa/floretyrosine-f-18) | TLX |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218592_20250425.pdf%22)) |
| April 23, 2025 | [Eylea® (eylea) complete response letter (CRL)](https://sec-api.dev/pdufa/eylea) | REGN |  | completed, complete response letter | "•The FDA issued a Complete Response Letter (CRL) for the EYLEA HD pre-filled syringe on April 23, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| April 2, 2025 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA216442_20250402.pdf%22)) |
| Apr 2025 | [Aldeyra Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | completed, complete response letter | "In April 2025, Aldeyra received a Complete Response Letter from the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000121390025054949/ea0245870ex99-1_aldeyra.htm)) |
| Apr 2025 | [EBVALLOTM (ebvallotm) complete response letter (CRL)](https://sec-api.dev/pdufa/ebvallotm) | ATRA |  | completed, complete response letter | "In April 2025, Atara paused its review of strategic options, pending the Type A meeting with the FDA which is scheduled in the second quarter of 2025, to discuss the plan to address the issues raised by the FDA in the CRL and the path forward for resubmission of the EBVALLOTM BLA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/d106735dex991.htm)) |
| March 27, 2025 | [CARDAMYST (etripamil) complete response letter (CRL)](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218571_20250327.pdf%22)) |
| February 27, 2025 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed, complete response letter | "Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we resubmitted the BLA application for ONS-5010/LYTENAVA on February 27, 2025 and received a CRL on August 28, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm)) |
| January 17, 2025 | [Nda219112 complete response letter (CRL)](https://sec-api.dev/pdufa/nda219112) | PFE |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219112_20250117.pdf%22)) |
| January 16, 2025 | [EBVALLOTM (ebvallotm) complete response letter (CRL)](https://sec-api.dev/pdufa/ebvallotm) | ATRA |  | completed, complete response letter | "The clinical hold was directly linked to GMP compliance issues identified during the pre-license inspection of the third-party manufacturing facility referenced in the Complete Response Letter (CRL) for EBVALLOTM that was announced on January 16, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525113811/d905721dex991.htm)) |
| January 15, 2025 | [Tab-cel (tabelecleucel) complete response letter (CRL)](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 01/15/2025 for BL 125745 to Atara Biotherapeutics, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125745_20250115.pdf%22)) |
| Jan 2025 | [ATA3219 complete response letter (CRL)](https://sec-api.dev/pdufa/ata3219) | ATRA |  | completed, complete response letter | "Atara received a clinical hold notice from FDA on EBVALLO studies linked to the CRL in January 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017025035482/atra-ex99_1.htm)) |
| December 20, 2024 | [INPEFA® (sotagliflozin) complete response letter (CRL)](https://sec-api.dev/pdufa/sotagliflozin) | LXRX | type 1 diabetes and CKD | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA210934_20241220.pdf%22)) |
| December 13, 2024 | [Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) complete response letter (CRL)](https://sec-api.dev/pdufa/amivantamab-and-hyaluronidase-lpuj) | JNJ |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761433_20241213.pdf%22)) |
| Dec 2024 | [ZYNQUISTA® (zynquista) complete response letter (CRL)](https://sec-api.dev/pdufa/zynquista) | LXRX | type 1 diabetes and CKD | completed, complete response letter | "The FDA issued an additional complete response letter in December 2024 regarding our NDA for ZYNQUISTA as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and CKD." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/lxrx-20251231.htm)) |

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CRL tracker: FDA complete response letters." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/crl-tracker

```bibtex
@misc{secapidev_crl_tracker_20261116,
  title        = {CRL tracker: FDA complete response letters},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/crl-tracker}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_crl_tracker_20261116","title":"CRL tracker: FDA complete response letters","publisher":"sec-api.dev","URL":"https://sec-api.dev/crl-tracker","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
